Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 418 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADHD Therapy Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 6, 2026, 3:05 AM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 1 Interventional

Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies

NCT01073176
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
TEAMS (Training Attention Executive and Motor Skills)
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
4 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 6, 2026, 3:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

NCT01114737
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sapropterin dihydrochloride, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
8 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 6, 2026, 3:05 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00886483
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Active Neurofeedback, Sham neurofeedback
Device
Lead sponsor
L. Eugene Arnold
Other
Eligibility
6 Years to 12 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Sep 6, 2026, 3:05 AM EDT
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 6, 2026, 3:05 AM EDT
Completed No phase listed Observational

Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population

NCT02251080
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

NCT02478788
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
mixed amphetamine salts-extended release (MAS-XR), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 2 Interventional

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

NCT00142961
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions
Atomoxetine, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 6, 2026, 3:05 AM EDT
Terminated Not applicable Interventional Results available

Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors

NCT01749800
View directory record Official record
Conditions
TBI, Attention Deficits, Motor Impairments
Interventions
GVS, Sham GVS, Armeo Spring
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

Further Studies of Attention Deficit Disorder - Residual Type (RT)

NCT00693212
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 6, 2026, 3:05 AM EDT
Terminated Phase 2 Interventional Results available

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

NCT03638466
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions
Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo
Diagnostic Test · Behavioral · Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Lakeland, Florida • Maitland, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders

NCT00402857
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Interventions
Incredible Years Program
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
22 Months to 38 Months
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
9
States / cities
Chelsea, Massachusetts • Dorchester, Massachusetts • Jamaica Plain, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 6, 2026, 3:05 AM EDT
Active, not recruiting Phase 4 Interventional

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

NCT05469386
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 6, 2026, 3:05 AM EDT
Terminated Phase 4 Interventional Results available

A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT01721330
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

NCT00626236
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Interventions
SPN-810
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Bradenton, Florida • Gainesville, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 6, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 6, 2026, 3:05 AM EDT